AstraZeneca Goodwill and Intangible Assets 2010-2024 | AZN

AstraZeneca goodwill and intangible assets from 2010 to 2024. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
  • AstraZeneca goodwill and intangible assets for the quarter ending September 30, 2024 were $60.533B, a 5.04% increase year-over-year.
  • AstraZeneca goodwill and intangible assets for 2023 were $58.137B, a 1.67% decline from 2022.
  • AstraZeneca goodwill and intangible assets for 2022 were $59.127B, a 5.22% decline from 2021.
  • AstraZeneca goodwill and intangible assets for 2021 were $62.384B, a 90.24% increase from 2020.
AstraZeneca Annual Goodwill and Intangible Assets
(Millions of US $)
2023 $58,137
2022 $59,127
2021 $62,384
2020 $32,792
2019 $32,501
2018 $33,666
2017 $38,013
2016 $39,244
2015 $34,446
2014 $32,531
2013 $26,028
2012 $26,346
2011 $20,842
2010 $22,029
2009 $22,115
AstraZeneca Quarterly Goodwill and Intangible Assets
(Millions of US $)
2024-09-30 $60,533
2024-06-30 $60,486
2024-03-31 $58,812
2023-12-31 $58,137
2023-09-30 $57,626
2023-06-30 $58,286
2023-03-31 $59,292
2022-12-31 $59,127
2022-09-30 $59,292
2022-06-30 $59,721
2022-03-31 $61,228
2021-12-31 $62,384
2021-09-30 $64,185
2021-06-30 $31,804
2021-03-31 $32,112
2020-12-31 $32,792
2020-09-30 $32,324
2020-06-30 $31,373
2020-03-31 $31,287
2019-12-31 $32,501
2019-09-30 $33,049
2019-06-30 $33,925
2019-03-31 $34,526
2018-12-31 $33,666
2018-09-30 $36,147
2018-06-30 $36,604
2018-03-31 $37,684
2017-12-31 $38,013
2017-09-30 $38,965
2017-06-30 $39,239
2017-03-31 $39,074
2016-12-31 $39,244
2016-09-30 $40,313
2016-06-30 $41,286
2016-03-31 $41,615
2015-12-31 $34,446
2015-09-30 $31,427
2015-06-30 $31,953
2015-03-31 $31,706
2014-12-31 $32,531
2014-09-30 $31,719
2014-06-30 $32,710
2014-03-31 $33,133
2013-12-31 $26,028
2013-09-30 $27,199
2013-06-30 $26,349
2013-03-31 $25,932
2012-12-31 $26,346
2012-09-30 $26,575
2012-06-30 $23,496
2012-03-31 $20,898
2011-12-31 $20,842
2011-09-30 $21,535
2011-06-30 $21,949
2011-03-31 $22,122
2010-12-31 $22,029
2010-09-30 $22,823
2010-06-30 $22,678
2010-03-31 $22,906
2009-12-31 $22,115
2009-09-30 $22,123
2009-06-30 $21,985
2009-03-31 $21,895
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $197.819B $45.811B
AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94